A Comprehensive Review of Extragenital Lichen Sclerosus in the Medical Literature
Clinical Scorecard: A Comprehensive Review of Extragenital Lichen Sclerosus in the Medical Literature
At a Glance
Category Detail
Condition Extragenital Lichen Sclerosus (ELS) Key Mechanisms Autoimmune mechanisms, genetic predisposition, hormonal influences, Koebner phenomenon. Target Population Middle-aged adults, predominantly women. Care Setting Dermatology clinics, outpatient settings.
Key Highlights
Affects 15-20% of patients with lichen sclerosus, rarely as an isolated form. Lesions are typically asymptomatic or mildly pruritic, commonly on neck, trunk, and upper extremities. High-potency topical corticosteroids are first-line therapy; refractory cases may require phototherapy or systemic methotrexate. Diagnosis is primarily clinical, confirmed by histopathology; skin biopsy is the gold standard. No increased risk of squamous cell carcinoma associated with ELS. Guideline-Based Recommendations
Diagnosis
Clinical diagnosis supported by histopathology. Dermoscopy and confocal microscopy may assist in diagnosis. Management
First-line treatment with high-potency topical corticosteroids. Consider UVA1 or nbUVB phototherapy and systemic methotrexate for refractory cases. Monitoring & Follow-up
Regular follow-up to assess treatment response and manage any complications. Risks
ELS lesions are resistant to treatment, particularly the bullous variant. Patient & Prescribing Data
Middle-aged adults, predominantly women with ELS.
Topical corticosteroids are effective; other treatments are limited to refractory cases.
Clinical Best Practices
Conduct thorough clinical evaluations to confirm diagnosis. Utilize histopathological confirmation in ambiguous cases. Educate patients about the chronic nature of the disease and treatment options. References
